Pfizer (PFE) TD Cowen 46th Annual Health Care Conference summary

External environment and policy changes

• Negotiations with U.S. government removed major uncertainties around tariffs and drastic pricing adjustments, benefiting the industry and setting a precedent for other companies.

• U.K. committed to increase spending on innovative medicines, signaling positive international pricing trends.

• Recent PBM reforms and regulatory changes are expected to improve transparency and reduce out-of-pocket costs for patients.

• U.S. trade negotiations may further support innovation and favorable pricing for new products.

Strategic priorities and business outlook

• Focus for 2025 is on maximizing value from recent $80 billion acquisitions, especially Seagen, Becerra, and Biohaven.

• Delivering key R&D milestones, including regulatory approvals and 20 phase III studies, is a top priority.

• Plans to maintain dividends while investing in R&D and commercial infrastructure to drive post-LOE growth.

• Double-digit growth expected from newly launched and acquired products, with a strong outlook through 2028.

Pipeline and product development

• Oncology is a major focus, with pivotal phase III studies for Seagen's SV compound and Mirati portfolio launches targeted for 2028.

• Vaccine pipeline includes Lyme disease, C. difficile, and next-generation pneumococcal vaccines, aiming to maintain market leadership.

• Obesity portfolio features differentiated monthly and next-generation products, with phase III studies underway and potential for further innovation.

• Commercial strategies include leveraging consumer brand equity and direct-to-consumer approaches, with insights gained from the Chinese market.